Le Lézard
Classified in: Health, Covid-19 virus
Subjects: CALENDAR OF EVENTS, TRADE SHOWS/SEMINARS/WEBINARS

Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202


WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial in Q1 2023.

November 2022:

Poster of Camsirubicin Phase 1b Clinical Trial Data to be Presented at CTOS 2022

Event: Connective Tissue Oncology Society (CTOS) Annual Meeting Conference
Date: November 16-19, 2022
Location: Vancouver Convention Centre, Vancouver, BC, Canada

December 2022:

Poster of MNPR-202 Preclinical Data to be Presented at ASH 2022

Event: 64th American Society of Hematology (ASH) Annual Meeting & Exposition
Date: December 10-13, 2022
Location: Ernest N. Morial Convention Center, New Orleans, Louisiana

Q1 2023:

Interim go/no-go Analysis for Validive Phase 2b/3 VOICE Clinical Trial

The Company plans to report out the interim go/no-go decision for its Validive Phase 2b/3 VOICE clinical trial in Q1 2023. All patients required for the interim analysis have been enrolled. Patient enrollment will continue, as will adding additional clinical sites (currently 71 sites across the U.S. and Europe), in preparation for a potentially positive interim analysis.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® (Phase 2b/3) for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:??

Monopar Therapeutics Inc.  
Investor Relations??  
Kim R. Tsuchimoto??  
Chief Financial Officer??  
[email protected]  

Follow Monopar on social media for updates:?  
Twitter: @MonoparTx? LinkedIn: Monopar Therapeutics  



These press releases may also interest you

at 10:55
SURFER Announces Partnership With 2024 Big Wave Challenge
The Arena Group, owner of SURFER, announced today its sponsorship of the 2024 Big Wave Challenge. Partnering with legendary big wave media pioneer Bill Sharp, co-producer of HBO's 100 Foot Wave, the reinvigorated Big Wave Challenge will recognize and...

at 10:19
FDA Takes Action Aimed at Helping to Ensure the Safety and Effectiveness of Laboratory Developed Tests
Today, the U.S. Food and Drug Administration took action aimed at helping to ensure the safety and effectiveness of laboratory developed tests, or LDTs, which are used in a growing number of health care decisions and about which concerns have been...

at 10:05
HD Nursing Honored as Silver Stevie® Award Winner in 2024 American Business Awards®
HD Nursing, the leading patient safety solution that combines predictive analytics with individualized fall and pressure injury prevention, was named the winner of a Silver Stevie® Award in the Company of the Year - Health Products & Services...

at 10:01
Online Food Delivery Market to Reach $1.3 Trillion, Globally, by 2032 at 14.3% CAGR: Allied Market Research
Allied Market Research published a report, titled, "Online Food Delivery Market by Type (Restaurant-To-Consumer and Platform-To-Consumer), Channel Type (Websites/Desktop and Mobile Applications), and...

at 10:00
Cold Spring Harbor Laboratory and Northwell Health extend strategic affiliation
Leaders from two of New York's preeminent bioscience and healthcare institutions came together at Carnegie Hall to acknowledge the signing of an update to their affiliation agreement initiated in 2015. The Cold Spring Harbor Laboratory-Northwell...

at 09:59
Pandemic Fatigue and Vaccine Hesitancy Continue to Affect Global Public Health, New 23-country Study in Nature Medicine Reports
While it found that global uptake of at least one COVID-19 vaccine dose was robust, a new survey published today in Nature Medicine revealed mixed signals about the current acceptance of vaccines generally, especially COVID-19 boosters. The new...

More news about Covid-19 virus...


News published on and distributed by: